Paediatric lymphoblastic lymphoma: a national review of 20 years of clinical and biological data in Ireland
Authors:
Open Access
- 18 November 2025
- journal article
- review article
- Published by Springer Nature in Annals of Hematology
- Vol. 104 (12) , 6297-6304
Abstract
Lymphoblastic lymphoma (LBL) is a rare, aggressive malignancy comprising T-cell (T-LBL) and B-cell (B-LBL) subtypes. While outcomes for LBL have improved, comprehensive national data on clinical and biological features remain limited. We conducted a retrospective review of children and adolescents with LBL in Ireland over 20 years (2004–2023). Data on demographics, clinical presentation, tumour characterization, treatment protocols, and outcomes were analysed. The cohort included 52 patients: 79% with T-LBL and 21% with B-LBL. T-LBL cases predominantly affected males (2.2:1) and presented with advanced disease, including mediastinal masses (98%) and high lactate dehydrogenase levels. B-LBL cases had a female predominance (0.4:1) and localized disease (82%). Survival outcomes were excellent for B-LBL, with 5-year event-free survival (EFS) and overall survival (OS) of 100%. For T-LBL, 5-year EFS and OS were 85%. Relapsed/refractory disease occurred in 4% (T-LBL only). Genetic, Minimal Disseminated Disease and Minimal Residual Disease analyses were limited. LBL outcomes in Ireland align with international reports, highlighting favourable survival but underscoring the need for improved risk stratification and genetic profiling, particularly for T-LBL.Keywords
This publication has 35 references indexed in Scilit:
- NOTCH1 fusions in pediatric T‐cell lymphoblastic lymphoma: A high‐risk subgroup with CCL17 (TARC) levels as diagnostic biomarkerHemaSphere, 2024
- Diagnosis and management of lymphoblastic lymphoma in children, adolescents and young adultsBest Practice & Research Clinical Haematology, 2023
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid NeoplasmsLeukemia, 2022
- Oncogenetic landscape of T-cell lymphoblastic lymphomas compared to T-cell acute lymphoblastic leukemiaLaboratory Investigation, 2022
- Impact of dose and duration of therapy on dexamethasone pharmacokinetics in childhood acute lymphoblastic leukaemia—a report from the UKALL 2011 trialEuropean Journal of Cancer, 2019
- Relapsed or Refractory Lymphoblastic Lymphoma in Children: Results and Analysis of 23 Patients in the EORTC 58951 and the LMT96 ProtocolsPediatric Blood & Cancer, 2016
- Detection and role of minimal disseminated disease in children with lymphoblastic lymphoma: The AIEOP experiencePediatric Blood & Cancer, 2015
- Outcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2012
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemiaThe Lancet Oncology, 2009
- Retrospective analysis of relapsed or primary refractory childhood lymphoblastic lymphoma in JapanPediatric Blood & Cancer, 2009